GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Price-to-Owner-Earnings

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Price-to-Owner-Earnings : (As of Jun. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Price-to-Owner-Earnings?

As of today (2024-06-16), Suzhou Zelgen Biopharmaceuticals Co's share price is ¥58.25. Suzhou Zelgen Biopharmaceuticals Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings or its related term are showing as below:


SHSE:688266's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.65
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-16), Suzhou Zelgen Biopharmaceuticals Co's share price is ¥58.25. Suzhou Zelgen Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-1.00. Therefore, Suzhou Zelgen Biopharmaceuticals Co's PE Ratio for today is At Loss.

As of today (2024-06-16), Suzhou Zelgen Biopharmaceuticals Co's share price is ¥58.25. Suzhou Zelgen Biopharmaceuticals Co's EPS without NRI for the trailing twelve months (TTM) ended in was ¥-1.03. Therefore, Suzhou Zelgen Biopharmaceuticals Co's PE Ratio without NRI for today is At Loss.


Suzhou Zelgen Biopharmaceuticals Co Price-to-Owner-Earnings Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Price-to-Owner-Earnings Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings falls into.



Suzhou Zelgen Biopharmaceuticals Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=58.25/-1.17
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Suzhou Zelgen Biopharmaceuticals Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Traded in Other Exchanges
N/A
Address
No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Executives
Zhang Bin Core technical personnel
Huang Gang senior management
Lv Bin Hua Directors, senior managers, core technical personn
Lu Hui Ping Directors, senior managers
Gao Qing Ping senior management
Wu Ji Sheng Directors, senior managers, core technical personn
Zhang Jun Li senior management
Wu Li Qing Core technical personnel
Core technical personnel
Sheng Ze Lin Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines